MedPath

UVA Light Device to Treat COVID-19

Not Applicable
Completed
Conditions
Coronavirus
Interventions
Device: UV Light Treatment
Registration Number
NCT04572399
Lead Sponsor
Cedars-Sinai Medical Center
Brief Summary

This pilot study will assess the safety and effectiveness of UV light treatment in hospitalized patients with COVID-19.

Detailed Description

This is a single center, open label, pilot study. 5 adult patients, aged over 18, who are confirmed positive with SARS-CoV-2 and are newly intubed, will receive UV light treatment to reduce SARS-CoV-2 viral load.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
5
Inclusion Criteria
  • Confirmed positive test result for SARS-CoV-2
  • Mechanically ventilated
  • Endotracheal tube inner diameter of at least 7.5 mm
Exclusion Criteria
  • Unable to provide informed consent (or surrogate)
  • Enrolled in a therapeutic clinical trial for same condition that does not allow recruitment in other trials
  • Pregnant women

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Endotracheal UV LightUV Light TreatmentMechanically ventilated patients who will receive UV Light therapy
Primary Outcome Measures
NameTimeMethod
Negative Change in Viral Load5 days

Change of viral load in upper airway in patients admitted to hospital for COVID-19

Secondary Outcome Measures
NameTimeMethod
Change in Bacterial Load5 days

Change of bacterial load in upper airway

Ventilated Associated Pneumonia1 month

Percentage of patients developing ventilated pneumonia (VAP) within 30 days of treatment

Catheter Tip Assessment on the Last Day of Treatment5 days

Assessment of total bacterial load on the UV catheter tip on the last day of treatment

Days to Extubation1 month

Number of days patient is intubated with endotracheal tube or tracheostomy

Days to Discharge1 month

Number of days patient is discharged from the hospital

Change in C-reactive Protein5 days

Change in C-reactive protein from baseline to the end of the treatment

Change in the World Health Organization (WHO) Coronavirus Disease (COVID)-19 10-point Ordinal Severity Scale by 30 Days1 month

The World Health Organization (WHO) COVID-19 10-point ordinal severity scale:

0 uninfected, No viral RNA detected

1. Asymptomatic; viral RNA detected

2. Ambulatory Mild disease: Symptomatic; independent

3. Ambulatory Mild disease: Symptomatic; assistance needed

4. Hospitalized: Moderate disease; no oxygen therapy

5. Hospitalized: Moderate disease; oxygen by mask or nasal prongs

6. Hospitalized: sever disease, Oxygen by non-invasive ventilation or high flow

7. Hospitalized: severe disease, intubation and mechanical ventilation, pO2/FiO2\>=150 or SpO2/FiO2\>=200

8. Hospitalized: severe disease, Mechanical ventilation pO2/FiO2\<150(SpO2/FiO2 \<200) or vasopressors

9. Hospitalized: severe disease, Mechanical ventilation pO2/FiO2\<150 and vasopressors, dialysis or extracorporeal membrane oxygenation

10. Death

Trial Locations

Locations (1)

Cedars-Sinai Medical Center

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath